Results 1 to 10 of about 37,324 (186)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021 [PDF]

Blood Cancer Journal, 2021
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients ...
M. Hasib Sidiqi, Morie A. Gertz
doaj   +3 more sources

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics [PDF]

Nature Communications, 2022
Immunoglobulin light chain amyloidosis is a lethal hematologic disorder driven by clonal plasma cells producing abnormal light chains that damage healthy tissues. Fraser et al.
Cameron S. Fraser, Johan K. E. Spetz, Xingping Qin, Adam Presser, Jonathan Choiniere, Chendi Li, Stacey Yu, Frances Blevins, Aaron N. Hata, Jeffrey W. Miller, Gary A. Bradshaw, Marian Kalocsay, Vaishali Sanchorawala, Shayna Sarosiek, Kristopher A. Sarosiek   +14 more
doaj   +3 more sources

Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment. [PDF]

J Natl Compr Canc Netw, 2023
Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder with multiple clinical presentations. The diagnosis of AL amyloidosis requires a high index of suspicion, making a delay in diagnosis common, which contributes to the high early
Zanwar S, Gertz MA, Muchtar E.
europepmc   +2 more sources

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

New England Journal of Medicine, 2021
BACKGROUND Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.
Efstathios Kastritis, Giovanni Palladini, Ashutosh D Wechalekar   +2 more
exaly   +2 more sources

The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. [PDF]

Insights Imaging, 2022
Cardiac magnetic resonance (CMR) imaging is a key test in the diagnosis of cardiac amyloidosis (CA). Extracardiac involvement is common in light chain (AL) amyloidosis and MRI findings may assist in its diagnosis.
Lama N, Briasoulis A, Karavasilis E, Stamatelopoulos K, Chasouraki A, Alexopoulou E, Spiliopoulos S, Theodorakakou F, Dimopoulos MA, Kastritis E, Kelekis NL.   +10 more
europepmc   +2 more sources

Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications. [PDF]

Exp Hematol Oncol, 2021
Immunoglobulin light chain amyloidosis (AL) is an indolent plasma cell disorder characterized by free immunoglobulin light chain (FLC) misfolding and amyloid fibril deposition.
Xu L, Su Y.
europepmc   +2 more sources

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +2 more sources

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis. [PDF]

Blood
Immunoglobulin light chain (AL) amyloidosis is a plasma cell disorder characterized by progressive organ dysfunction secondary to deposition of organized immunoglobulin light chain aggregates.
Vianna P, Chakraborty R, Hossain S, Bhutani D, Miller S, Rossi A, Cuddy SAM, Falk RH, Lentzsch S, Laubach JP, Bianchi G.   +10 more
europepmc   +2 more sources

Localized Immunoglobulin Light-Chain Amyloidosis of the Ulnar Nerve [PDF]

Case Reports in Neurology, 2021
Amyloidosis is a disorder caused by extracellular tissue deposition of insoluble fibrils. Amyloidosis can be divided into systemic or localized disease. Primary systemic amyloidosis is a multisystem disease caused by the deposition of amyloid in various ...
Shinsuke Morisaki, Shinji Tsuchida, Eiichi Konishi, Nagaaki Katoh, Yusuke Takahashi, Kenji Takahashi   +5 more
doaj   +2 more sources

Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis. [PDF]

Hematol Oncol Clin North Am, 2020
Stem cell transplantation was one of the first proven effective regimens for the management of immunoglobulin light-chain amyloidosis. Criteria for patient selection and the mobilization regimen become important features in ensuring a safe outcome.
Gertz MA, Schonland S.
europepmc   +2 more sources